Researchers have analysed the therapeutic benefits of an antiviral drug, nirmatrelvir, and a class of drugs typically used for bone disorders, bisphosphonates, on the coronavirus. Nirmatrelvir treatment proved effective in preventing severe disease but might impact the host immune system’s ability to combat the virus in future. Meanwhile, bisphosphonates were found to enhance antibody responses to viral antigens, reducing COVID-19 risk and hospitalisation rates.
What’s Next for Healthcare Cybersecurity After a Tumultuous 2024?
Cybersecurity breaches in the healthcare sector are increasing, with ransomware and data exfiltration attacks becoming more frequent. In response, Chief Information Security Officers are putting
